Optimized Treatment and Regression of HBV-induced Early Cirrhosis

Exclusion Criteria

• •1. Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or hepatocelluar carcinoma;
• •2. Patients who are allergic to entecavir, thymosin or their components, and those considered not suitable for drugs used in this study;
• •3. Patients with HCV or HIV infection, alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty liver disease or other chronic liver diseases;
• •4. Patients with baseline AFP level higher than 100 ng/ml and possible malignant lesion on image, or AFP level higher than 100 ng/ml for more than three months;
• •5. Creatinine \>1.5×ULN;
• •6. Patients with other uncured malignant tumors;
• •7. Patients with severe diseases of heart, lung, kidney, brain, blood or other organs;
• •8. Patients with any other reasons not suitable for the study.